Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Status:
RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. The main question it aims to answer is:
• Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?
Phase:
PHASE3
Details
Lead Sponsor:
University of Heidelberg Medical Center
Collaborators:
Bristol-Myers Squibb KKS Netzwerk Sanofi Wuerzburg University Hospital